HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Mersana Therapeutics (MRSN) Investors with Substantial Losses to Contact Firm’s Attorneys, Firm Investigating Possible Securities Law Violations SAN FRANCISCO, July 24, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Mersana Therapeutics, Inc. (NASDAQ: MRSN) investors who suffered substantial losses to submit your losses now. Visit:...

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Mersana Therapeutics (MRSN) Investors with Substantial Losses to Contact Firm’s Attorneys, Firm Investigating Possible Securities Law Violations SAN FRANCISCO, July 03, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Mersana Therapeutics, Inc. (NASDAQ: MRSN) investors who suffered substantial losses to submit your losses now. Visit:...

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Mersana Therapeutics (MRSN) Investors with Substantial Losses to Contact Firm’s Attorneys, Firm Investigating Possible Securities Law Violations SAN FRANCISCO, June 26, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Mersana Therapeutics, Inc. (NASDAQ: MRSN) investors who suffered substantial losses to submit your losses now. Visit:...

Mersana Therapeutics Shareholder Alert: Kaplan Fox Launches Investigation into Mersana Therapeutics, Inc. for Potential Securities Violations NEW YORK, June 23, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating potential claims on behalf of investors who purchased Mersana Therapeutics, Inc....

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Mersana Therapeutics (MRSN) Investors with Substantial Losses to Contact Firm’s Attorneys, Firm Investigating Possible Securities Law Violations SAN FRANCISCO, June 20, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Mersana Therapeutics, Inc. (NASDAQ: MRSN) investors who suffered substantial losses to submit your losses now. Visit:...